Digital Health Technologies & Digital Biomarkers
Optimise protocol strategies with fit-for-purpose digital measures
ICON supports sponsors in accelerating and improving the assessment, selection and deployment of evidence-backed digital measures in clinical trials.
Our proprietary Atlas platform provides the most comprehensive insights on AI-powered biomarkers, multi-modal technologies, wearable sensors and other digital health technologies.
With 18,000+ digital measures gathered from 3,600 connected sensors spanning more than 1,300 medical conditions across 20 therapeutic areas and backed by more than 15,000 pieces of evidence, deploying the Atlas platform early in the trial lifecycle helps de-risk endpoint selection and optimize protocol design, and ensures the prioritisation of patient-centred outcomes.
The Atlas platform is based on comprehensive data:
-
19,000+
digital measures and biomarkers -
3,600+
digital health technologies
-
1,700
clinical trials -
15,000+
peer reviewed publications, research papers and conference abstracts
Atlas benefits:
- De-risk trial deployment with validated, scientifically-backed tools and assessments to capture robust data
- Optimise protocol strategies throughout the trial lifecycle, increasing likelihood of regulatory approval
- Development of patient-centered clinical strategies, reducing participation burden and measuring what matters to patients
- 4x faster decision making with Atlas compared to using traditional research methods
Media contributions
Blog contributions
-
Blog: How COAs and DHTs offer deep insights into patient experiences and treatment effects
A conversation with Sonia Bothorel, Managing Director, Mapi Research Trust and Outcome Measures Solutions.
-
Blog: Why using COAs and DHTs together is the future of clinical research
Though both COAs and DHTs are tools used to evaluate a treatment’s impact, they often exist in separate spheres. We argue that combining these two approaches in the same study can help researchers gather better data and improve the likelihood of regulatory approval.
-
Blog: Digital health: Why evaluating human factors is essential
With the rapidly evolving technology, digital health is transforming healthcare, emerging as a promising solution to reduce rising healthcare costs and improve patient care.
-
Blog: Digital health: Managing cybersecurity risks
When developing a new digital health device, as well as maintaining an existing device, securing the device from cybersecurity attacks is critical.
-
Blog: Utilising connected sensors to power diverse and equitable clinical trials
Our publication in Nature npj Digital Medicine outlines current evidence and a solution framework for diversity in research using digital health technologies.
-
Blog: Tested, tried and true: Why digital biomarkers are the AI & ML strategy pharma should prioritise
Rather than chasing generative AI, pharma executives can focus their AI & machine learning (ML) strategies for drug development on investing in and deploying connected sensors to reduce costs & improve patient outcomes.
.jpg?crop=yes&w=555&h=339&a=0,0&itok=q1F4Z6iQ "Insights-page-(1)"){kind=icon}
mHealth & Wearables insights
Our mHealth & Wearables insights will help you to understand and successfully address the complexities of implementation of wearable devices in trial design, execution and reporting.
Learn more
Request an Atlas platform demo or arrange a meeting